ZA200610786B - Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions - Google Patents

Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions

Info

Publication number
ZA200610786B
ZA200610786B ZA200610786A ZA200610786A ZA200610786B ZA 200610786 B ZA200610786 B ZA 200610786B ZA 200610786 A ZA200610786 A ZA 200610786A ZA 200610786 A ZA200610786 A ZA 200610786A ZA 200610786 B ZA200610786 B ZA 200610786B
Authority
ZA
South Africa
Prior art keywords
modulators
diabetes
peptide
treatment
related conditions
Prior art date
Application number
ZA200610786A
Inventor
William R Ewing
Richard B Sulsky
Ving G Lee
Rogelio L Martinez
Mapelli Claudio
Tasir S Haque
Riexinger Douglas James
Zhu Yeheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200610786B publication Critical patent/ZA200610786B/en

Links

ZA200610786A 2004-07-02 2006-12-20 Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions ZA200610786B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58535804P 2004-07-02 2004-07-02

Publications (1)

Publication Number Publication Date
ZA200610786B true ZA200610786B (en) 2008-12-31

Family

ID=38698080

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610786A ZA200610786B (en) 2004-07-02 2006-12-20 Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions

Country Status (2)

Country Link
CN (1) CN101010339B (en)
ZA (1) ZA200610786B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (en) 2010-12-16 2018-03-09 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104203221A (en) 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） Compositions comprising a delivery agent and preparation thereof
PT2827845T (en) 2012-03-22 2019-03-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
HUE062740T2 (en) * 2012-03-22 2023-12-28 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (en) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス Tablet formulation containing peptide and delivery agent
TWI726889B (en) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 Protease-resistant lipidated peptides
SG10201911851VA (en) * 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
CN111683676B (en) 2018-02-02 2024-06-18 诺和诺德股份有限公司 Solid composition comprising a GLP-1 agonist, a salt of N- (8- (2-hydroxybenzoyl) amino) octanoic acid and a lubricant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050037004A (en) * 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Analogues of glp-1

Also Published As

Publication number Publication date
CN101010339B (en) 2011-11-09
CN101010339A (en) 2007-08-01

Similar Documents

Publication Publication Date Title
IL180434A0 (en) Human glucagon - like - peptide - 1 modulators and their use in the treatment of diabetes and related conditions
HUP0700151A2 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
ZA200610786B (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
HUS2200006I1 (en) Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
DK3524261T3 (en) EXENDIN FOR USE IN THE TREATMENT OF DIABETES AND REDUCTION OF BODY WEIGHT
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP1799263A4 (en) Reducing er stress in the treatment of obesity and diabetes
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
ZA200808699B (en) Light emitting device for use in therapeutic and/or cosmetic treatment
GB0523576D0 (en) Drug composition and its use in therapy
PL3542869T3 (en) Disposable sleep and breathing monitor
EP1789109A4 (en) Dialysis implant and methods of use
PL1831149T3 (en) Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
EP1814909A4 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
EP2097107A4 (en) Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP1768583A4 (en) Electro-stimulation and medical delivery device
EP1909689A4 (en) Drug-containing implants and methods of use thereof
AU2003202075A1 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
ZA200710800B (en) Melthod and apparatus for the non-invasive sensing of glucose in a human subject
EP1733045A4 (en) Design and therapeutic use of adpase enhanced apyrases
EP1802350A4 (en) Modulation of neuroglia-derived bdnf in the treatment and prevention of pain
AU2003226537A8 (en) Modulators of the notch signalling pathway and uses thereof in medical treatment
EP1773882A4 (en) Diagnosis and treatment of siglec-6 associated diseases
GB0420734D0 (en) Improvements in or relating to the therapeutic use of radiation and apparatus therefor
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss